tert-butyl 2-(2-ethoxy-1-imino-2-oxoethyl)hydrazine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl 2-(2-ethoxy-1-imino-2-oxoethyl)hydrazine-1-carboxylate
• 英文别名: ethyl (2E)-2-amino-2-[(2-methylpropan-2-yl)oxycarbonylhydrazinylidene]acetate
• 化学式: C₉H₁₇N₃O₄
• 分子量: 231.252
• InChiKey: KVYDKLDNFUYBAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-(2-ethoxy-1-imino-2-oxoethyl)hydrazine-1-carboxylate 在 吡啶 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 ethyl 5-(difluoromethyl)-2-methyl-1,2,4-triazole-3-carboxylate
  参考文献：
  名称：

  [EN] (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA
  [FR] DÉRIVÉS DE (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)MÉTHANONE UTILISÉS EN TANT QUE STABILISATEURS DE PAH MUTANTE POUR TRAITER LA PHÉNYLCÉTONURIE

  摘要：

  The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

  公开号：

  WO2023164233A1
• 作为产物：
  描述：

  肼基甲酸叔丁酯 、 硫代草氨酸乙酯 以 乙醇 为溶剂， 反应 24.0h， 以89%的产率得到tert-butyl 2-(2-ethoxy-1-imino-2-oxoethyl)hydrazine-1-carboxylate
  参考文献：
  名称：

  并行合成5位上带有杂环取代基的1 H -1,2,4-三唑-3-羧酸衍生物

  摘要：

  已经提出了一种温和的通用方法，该方法可从单一的前体乙基β- N -Boc-草并dra酮合成5个取代的1 H -1,2,4-三唑-3-羧酸的衍生物。该方法适用于1 H -1,2,4-三唑-3-羧酰胺库在5位杂环取代基的平行合成。

  DOI：

  10.1007/s10593-020-02794-2

文献信息

• ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF
  申请人：Beijing Scitech-MQ Pharmaceuticals Limited

  公开号：EP3901147A1

  公开（公告）日：2021-10-27

  Provided are an acylamino bridged heterocyclic compound of formula (I) or a pharmaceutically acceptable salt, an isomer, a solvate, a crystal, or a prodrug thereof, and a pharmaceutical composition comprising the compound, and an application of the compound or composition in drug preparation. The compound and the pharmaceutically acceptable salt, the isomer, the solvate, the crystal, or the prodrug thereof and the like can be used for treatment or prevention of autoimmune diseases, tumors, and neurodegenerative diseases related to receptor-interacting protein kinase-1 (RIPK1).

  本发明提供了一种式(I)的酰氨基桥杂环化合物或其药学上可接受的盐、异构体、溶解物、晶体或原药，以及包含该化合物的药物组合物，以及该化合物或组合物在药物制剂中的应用。 该化合物及其药学上可接受的盐、异构体、溶物、晶体或原药等可用于治疗或预防与受体相互作用蛋白激酶-1（RIPK1）有关的自身免疫性疾病、肿瘤和神经退行性疾病。
• [EN] ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE À PONT ACYLAMINO, COMPOSITION ET UTILISATION ASSOCIÉES<br/>[ZH] 酰胺基桥连杂环类化合物、及其组合物与应用
  申请人：BEIJING SCITECH MQ PHARMACEUTICALS LTD

  公开号：WO2020151589A1

  公开（公告）日：2020-07-30

  提供具有式(I)的酰胺基桥连杂环类化合物或其药学上可接受的盐、异构体、溶剂化物、结晶或前药，以及含有这些化合物的药物组合物和这些化合物或组合物在药物制备中的应用。这类化合物及其药学上可接受的盐、异构体、溶剂化物、结晶或前药等可用于与受体相互作用蛋白1激酶(RIPK1)相关的自身免疫性疾病、肿瘤以及神经退行性疾病的治疗或预防。
• EP3901147
  申请人：——

  公开号：——

  公开（公告）日：——
• ADENOSINE A2A AND A2B RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
  申请人：[en]MERCK SHARP & DOHME LLC

  公开号：WO2024118460A1

  公开（公告）日：2024-06-06

  In its many embodiments, the invention provides certain substituted amino triazolo quinazoline compounds of the structural Formula (I), and pharmaceutically acceptable salts thereof, wherein, ring A, R1and R2are as defined herein. Also provided are pharmaceutical compositions comprising one or more such compounds, alone or in combination with one or more other therapeutically active agents. Methods for the preparation of the compounds and their use as antagonists of A2a and/or A2b receptors, either alone or in combination with other therapeutic agents, in the treatment of a variety of diseases, conditions, or disorders that are mediated at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor, are also provided.
• [EN] PLASMA KALLIKREIN INHIBITORS<br/>[FR] INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
  申请人：[en]MERCK SHARP & DOHME LLC

  公开号：WO2023146809A1

  公开（公告）日：2023-08-03

  The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.